Efficacy of preoperative intravitreal injection of Conbercept combined with 25G+ pars plana vitrectomy in the treatment of proliferative diabetic retinopathy
10.3980/j.issn.1672-5123.2023.10.24
- VernacularTitle:术前玻璃体腔注射康柏西普联合25G+玻璃体切割术治疗增殖性糖尿病视网膜病变
- Author:
Yan-Hui HAN
1
;
Nan ZHAO
1
;
Fan-Chao MENG
1
;
Guang-Wei YU
1
;
Dong-Lin WANG
1
Author Information
1. Department of Fundus, Jinan Mingshui Eye Hospital, Jinan 250200, Shandong Province, China
- Publication Type:Journal Article
- Keywords:
proliferative diabetic retinopathy;
25G+ pars plana vitrectomy;
Conbercept;
adiponectin;
retinol binding protein 4
- From:
International Eye Science
2023;23(10):1732-1736
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To explore the efficacy of preoperative intravitreal injection of conbercept combined with 25G+ pars plana vitrectomy(PPV)in the treatment of proliferative diabetic retinopathy(PDR).METHODS: The clinical data of 154 patients(176 eyes)with PDR admitted to our hospital from January 2019 to June 2021 were collected for retrospective analysis. According to the treatment methods, 80 patients(92 eyes)in combined treatment group were treated with preoperative intravitreal injection of conbercept combined with 25G+PPV, and 74 patients(84 eyes)in control group were given 25G+PPV only. The postoperative clinical efficacy and levels of adipokines [adiponectin(APN), retinol binding protein 4(RBP4)] before and after surgery were compared between both groups of patients.RESULTS: The combined treatment group showed better clinical efficacy than the control group at 1mo after surgery(P<0.05). Both groups had lower RBP4 levels at 3mo after surgery(P<0.05), with the combined treatment group showing a lower level than the control group(P<0.05). Serum APN levels significantly increased in both groups after surgery(P<0.05), with the combined treatment group having a higher level than the control group(P<0.05). The combined treatment group had lower incidence rates of retinal proliferation and postoperative complications after than the control group 3mo of follow-up(P<0.05).CONCLUSION: Preoperative intravitreal injection of conbercept combined with 25G+PPV is beneficial in improving the therapeutic effect of PDR and reducing the incidence rates of complications, which may be related to the regulations of the expressions of adipokines.
